Monitoring for multiple myeloma

Arming providers with accurate testing for monitoring patients

Since the early 2000s, the average length of survival for patients with multiple myeloma, from time of diagnosis, has more than tripled to more than five years. While the use of monoclonal therapies has benefited patients greatly, it presents a unique challenge for laboratories as these therapies can cause interference with traditional gel immunofixation testing methods. The MASS-FIX methodology easily overcomes this issue for a majority of patients.

MASS-FIX is now included in International Myeloma Working Group recommendations as an accepted method for monitoring of M-protein-based diseases such as MGUS and multiple myeloma.

The most accurate testing for monitoring

The new MALDI-TOF MS testing method provides:

  • Increased sensitivity for early identification of myeloma relapse
  • Verifying if a patient’s IgG kappa mass is caused by monoclonal therapeutics or residual disease
  • Convenient, cost-effective, and clinically relevant information
  • Industry-leading turnaround times for results

Key testing

TMOGA | Monoclonal Gammopathy, Monitoring, Serum

Analytic Time: Same day/1 day 

Appropriate ordering scenario 

  • Determining if IgG kappa mass changes are caused by monoclonal therapeutics or residual disease

MALD | M-Protein Isotype, Matrix-Assisted Laser Desorption-Ionization Time-of-Flight Mass Spectrometry, Serum

Analytic Time: Same day/1 day 

Appropriate ordering scenario 

  • When protein electrophoresis and free light-chain testing is performed in-house; M-protein isotyping by MASS-FIX only 

Screening and Monitoring of Monoclonal Gammopathies

David Murray, M.D., Ph.D., provides an overview of the updated monoclonal gammopathy screening and monitoring tests for multiple myeloma. He discusses when this testing should be ordered, how this approach improves upon previous methods, and what clinical action can be taken from the results of these tests.

Minimal residual disease testing

Detecting minimal residual disease in bone marrow samples during treatment or after therapy has become increasingly important. Patients who do not achieve a minimal residual disease (MRD) negative status will relapse faster and have a shorter survival length.

With a sensitivity of 10(-5), our EuroFlow MRD test meets the guidelines recommended by the International Myeloma Working Group, the National Comprehensive Cancer Network, and the International Clinical Cytometry Society. Additionally, because most clinical trials require the use of MRD testing with at least a 10(-5) sensitivity, approaches that overcome the current limitations of conventional flow cytometry must be used.

Key testing

Learn more about how to order these evaluations at your institution.